ASH: Sanofi eyes FDA filing as orphan blood drug hits late-phase goal

[cafead]

via A phase 3 trial of Sanofi’s rare blood disease drug sutimlimab has met its primary endpoint. More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

article source